山梨医科大学雑誌　第12巻2号　045-051(1997)

The Effects of Epalrestat on Subjective Symptoms and Vibratory Threshold
in Type 2 Diabetic Patients with Neuropathy

Masato TAWATA, Kaoru AIDA, Masaharu INOUE, Akihiro KURIHARA, Eiichi IWASE,
Naoya GAN,
and Toshimasa ONAYA

Abstract: We evaluated the effects of epalrestat on subjective symptoms and vibration sensation in type 2 diabetic patients with neuropathy. The patients were administered epalrestat 150 mg/day orally in three divided doses for 3 months (treatment period), and the agent was discontinued for 3 months (washout period). Epalrestat relieved numbness in 12 of 16 patients after the treatment period, and numbness worsened in 5 of 11 patients after the washout period. Chi-square analysis revealed significant effects of epalrestat on numbness (p<0.001) and also on other symptoms (p<0.05). Vibration sensation was evaluated by measuring vibratory threshold using an SMV-5 vibrometer. The vibratory threshold significantly decreased in the upper (p<0.05) and the lower (p<0.01) extremities after the treatment period and increased in the lower extremity (p<0.05) after the washout period by paired t-test. There was no significant change in glycosylated hemoglobin as a whole during the study. These observations confirm that epalrestat relieves subjective symptoms and improves vibration sensation in type 2 diabetic patients with neuropathy without affecting glycemic control.

Key words: Epalrestat, Aldose reductase inhibitor, Diabetic neuropathy, Vibratory threshold, SMV-5 vibrometer




本文は、編集委員会の意向によりインターネットには公開しておりません。図書館等でご覧ください。

Texts are not availavle on Internet.



目次・Contentsに戻る